Robert Redner, MD
Hematology · Pittsburgh, PANPI 1851367684
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,666 of the $4,142 with a category attached, or 88.5%. 14 manufacturers reported payments, led by Novartis at 26.8% of the total. 2025 is the largest year on record at $1,611, 2.1 times the $781 reported in 2019.
Across 33 payments — averaging $125.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$698
- AbbVie$569
- E.r. Squibb & Sons, L.L.C.$341
- Daiichi Sankyo Inc.$284
- Amgen$233
- plus $906 from 8 others
Across 13 payments — averaging $11,365 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$126K
- Otsuka Pharmaceutical Co., Ltd.$9K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Bristol Myers Squibb$4K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Speaking & faculty fees$431%
- Travel & lodging$43310%
- Food & beverage$3,66689%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $1,112 |
| AstraZeneca | 8 | $698 |
| AbbVie | 5 | $569 |
| E.r. Squibb & Sons, L.L.C. | 3 | $341 |
| Daiichi Sankyo Inc. | 2 | $284 |
| Amgen | 2 | $233 |
| Astellas Pharma US Inc | 2 | $201 |
| Syndax Pharmaceuticals, Inc. | 1 | $127 |
| Geron Corporation | 1 | $123 |
| Stemline Therapeutics Inc. | 1 | $110 |
| Sobi, Inc | 1 | $106 |
| ADC Therapeutics America, Inc. | 1 | $103 |
| Incyte Corporation | 1 | $94 |
| Servier Pharmaceuticals LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,142 in reported general payments places this provider in the 65th percentile of 64 hematology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 24 | $358,639 |
| TasignaNilotinib Hcl | 11 | $221,581 |
| ImbruvicaIbrutinib | 12 | $195,487 |
| CalquenceAcalabrutinib Maleate | 13 | $194,590 |
| NinlaroIxazomib Citrate | 13 | $186,979 |
| Imatinib Mesylate | 17 | $37,538 |
| XareltoRivaroxaban | 11 | $5,807 |
| Hydroxyurea | 23 | $682 |
| Acyclovir | 38 | $595 |
| Allopurinol | 23 | $127 |
| Levofloxacin | 11 | $50 |
| Folic Acid | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $1,112 | $221,58111 claims |
| AstraZenecaCalquence | $698 | $194,59013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 64 hematology providers in Pennsylvania.
Other hematology in Pittsburgh
- Craig SeamanPittsburgh$88K
- Robert KaplanPittsburgh$46K
- Julia XuPittsburgh$33K
- Laura de CastroPittsburgh$16K
- Santhosh SadashivPittsburgh$15K
- Neal SpadaPittsburgh$698
- Erika MoorePittsburgh$110
- Olubusola OluwolePittsburgh$41
- Radhakrishnan RamchandrenWest Reading$233K
- Selina LugerPhiladelphia$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.